Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

AC Immune (ACIU) Invested Capital (2016 - 2025)

AC Immune has reported Invested Capital over the past 11 years, most recently at $74.5 million for Q4 2025.

  • Quarterly Invested Capital fell 50.71% to $74.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $74.5 million through Dec 2025, down 50.71% year-over-year, with the annual reading at $74.5 million for FY2025, 50.71% down from the prior year.
  • Invested Capital was $74.5 million for Q4 2025 at AC Immune, down from $78.1 million in the prior quarter.
  • Over five years, Invested Capital peaked at $229.4 billion in Q1 2021 and troughed at $74.5 million in Q4 2025.
  • The 5-year median for Invested Capital is $165.6 million (2023), against an average of $31.7 billion.
  • Year-over-year, Invested Capital surged 83345.96% in 2021 and then tumbled 99.9% in 2022.
  • A 5-year view of Invested Capital shows it stood at $275.1 million in 2021, then plummeted by 31.26% to $189.1 million in 2022, then increased by 5.49% to $199.4 million in 2023, then dropped by 24.19% to $151.2 million in 2024, then tumbled by 50.71% to $74.5 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Invested Capital are $74.5 million (Q4 2025), $78.1 million (Q3 2025), and $90.3 million (Q2 2025).